Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism

Nature Communications

Volumn 7, Issue , 2016, Pages

  Yang, Yunlong ^a,b   Zhang, Yin ^b   Iwamoto, Hideki ^b   Hosaka, Kayoko ^b   Seki, Takahiro ^b   Andersson, Patrik ^b   Lim, Sharon ^b   Fischer, Carina ^b   Nakamura, Masaki ^b   Abe, Mitsuhiko ^b   Cao, Renhai ^b   Skov, Peter Vilhelm ^c   Chen, Fang ^d   Chen, Xiaoyun ^e   Lu, Yongtian ^a   Nie, Guohui ^a   Cao, Yihai ^b,f  

^a THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d Zhejiang Provincial Traditional Chiese Medicine Hospital   (China)

^e SUN YAT SEN UNIVERSITY   (China)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; COLLAGEN TYPE 4; FIBRONECTIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LAMININ; SUNITINIB; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANTIBODY; CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; DRUG; PERMEABILITY; TUMOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BASEMENT MEMBRANE; CANCER CHEMOTHERAPY; CAPILLARY DENSITY; COLORECTAL CANCER; CONTROLLED STUDY; EXTRACELLULAR MATRIX; EXTRAVASATION; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; LIVER BLOOD VESSEL; LIVER CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER WEIGHT; LUNG METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPLEEN METASTASIS; TREATMENT WITHDRAWAL; TUMOR CELL INOCULATION; TUMOR VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; GENETICS; HUMAN; KNOCKOUT MOUSE; LIVER; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; FEMALE; HUMANS; INDOLES; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOPLASMS; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84984876330     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12680     Document Type: Article

References (59)

1. Cao, Y. et al. Forty-year journey of angiogenesis translational research. Sci. Transl. Med. 3, 114rv113 (2011).
2. Cao, Y. & Langer, R. Optimizing the delivery of cancer drugs that block angiogenesis. Sci. Transl. Med. 2, 15ps13 (2010).
3. Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049 (2008).
4. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
5. Tannock, I. F. et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 14, 760-768 (2013).
6. Garon, E. B. et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384, 665-673 (2014).
7. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
8. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
9. Motzer, R. J. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369, 722-731 (2013).
10. Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699-708 (2014).
11. D'Agostino, Sr R. B. Changing end points in breast-cancer drug approval - the Avastin story. N. Engl. J. Med. 365, e2 (2011).
12. Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484-2496 (2011).
13. Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563-572 (2009).
14. Loupakis, F. et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N. Engl. J. Med. 371, 1609-1618 (2014).
15. Hegewisch-Becker, S. et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 16, 1355-1369 (2015).
16. Tabernero, J. et al. Ramucirumab versus placebo in combination with secondline FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 16, 499-508 (2015).
17. Simkens, L. H. et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 385, 1843-1852 (2015).
18. Heinemann, V. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1065-1075 (2014).
19. Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
20. Hlushchuk, R., Makanya, A. N. & Djonov, V. Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again? Int. J. Dev. Biol. 55, 563-567 (2011).
21. Cao, Y., Zhong, W. & Sun, Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin. Cancer Biol. 19, 338-343 (2009).
22. Crawford, Y. et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15, 21-34 (2009).
23. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
24. Cao, Y. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs. Nat. Rev. Endocrinol. 10, 530-539 (2014).
25. Ferrara, N. Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 29, 789-791 (2009).
26. Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368-4380 (2002).
27. Cao, Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2 re1 (2009).
28. Shibuya, M. VEGF-VEGFR Signals in Health and Disease. Biomol Ther (Seoul) 22, 1-9 (2014).
29. Jubb, A. M. et al. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J. Clin. Pathol. 57, 504-512 (2004).
30. Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
31. Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009).
32. Yang, Y. et al. Anti-VEGF-and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc. Natl Acad. Sci. USA 110, 12018-12023 (2013).
33. Kamba, T. et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290, H560-H576 (2006).
34. Lim, S. et al. VEGFR2-mediated vascular dilation as a mechanism of VEGF-induced anemia and bone marrow cell mobilization. Cell Rep. 9, 569-580 (2014).
35. Honek, J. et al. Modulation of age-related insulin sensitivity by VEGFdependent vascular plasticity in adipose tissues. Proc. Natl Acad. Sci. USA 111, 14906-14911 (2014).
36. Yu, Y. et al. A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS ONE 5, e9072 (2010).
37. Yang, X. et al. Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA 110, 13932-13937 (2013).
38. Viloria-Petit, A. et al. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J. 22, 4091-4102 (2003).
39. Tam, B. Y. et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat. Med. 12, 793-800 (2006).
40. Zuniga, R. M. et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J. Neurooncol. 99, 237-242 (2010).
41. Shweiki, D., Itin, A., Soffer, D. & Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845 (1992).
42. LeCouter, J. et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299, 890-893 (2003).
43. Carmeliet, P. et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98, 147-157 (1999).
44. Lampugnani, M. G., Caveda, L., Breviario, F., Del Maschio, A. & Dejana, E. Endothelial cell-to-cell junctions. Structural characteristics and functional role in the regulation of vascular permeability and leukocyte extravasation. Baillieres Clin. Haematol. 6, 539-558 (1993).
45. De Craene, B. & Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13, 97-110 (2013).
46. Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71-78 (2004).
47. Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 6, 392-401 (2006).
48. Psaila, B. & Lyden, D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 9, 285-293 (2009).
49. Alix-Panabieres, C. & Pantel, K. Challenges in circulating tumour cell research. Nat. Rev. Cancer 14, 623-631 (2014).
50. Zhang, Y. et al. Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy. Proc. Natl Acad. Sci. USA 113, 4158-4163 (2016).
51. Iwamoto, H. et al. PlGF-induced VEGFR1-dependent vascular remodelling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors. Sci. Adv. 1, e1400244 (2015).
52. Jensen, L. D. et al. VEGF-B-Neuropilin-1 signaling is spatiotemporally indispensable for vascular and neuronal development in zebrafish. Proc. Natl Acad. Sci. USA 112, E5944-E5953 (2015).
53. Yang, X. et al. VEGF-B promotes cancer metastasis through a VEGF-Aindependent mechanism and serves as a marker of poor prognosis for cancer patients. Proc. Natl Acad. Sci. USA 112, E2900-E2909 (2015).
54. Xue, Y. et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat. Med. 18, 100-110 (2012).
55. Ji, H. et al. TNFR1 mediates TNF-alpha-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. Nat. Commun. 5, 4944 (2014).
56. Yang, Y. et al. The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages. Nat. Commun. 7, 11385 (2016).
57. Lim, S., Hosaka, K., Nakamura, M. & Cao, Y. Co-option of pre-existing vascular beds in adipose tissue controls tumor growth rates and angiogenesis. Oncotarget (2016).
58. He, B., Ebarasi, L., Hultenby, K., Tryggvason, K. & Betsholtz, C. Podocin-green fluorescence protein allows visualization and functional analysis of podocytes. J. Am. Soc. Nephrol. 22, 1019-1023 (2011).
59. Skov, P. V., Sorensen, T. F., Ramlov, H. & Steffensen, J. F. Vascular arrangement and ultrastructure of the European eelpout Zoarces viviparus ovary: implications for maternal-embryonic exchange. Anat Rec (Hoboken) 290, 1500-1507 (2007).